to establish primary patient derived organoid cultures from GM to study mechanisms that contribute to aggressive tumor growth and treatment resistance in primary and recurrent GM.
ID
Source
Brief title
Condition
- Nervous system neoplasms malignant and unspecified NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Intra-and inter organoid genetic and epigenetic heterogeneity that is
representative for GM
Secondary outcome
Not applicable
Background summary
Glioblastoma (GM) is the most frequent incurable adult brain tumor with median
survival of 15 months after diagnosis, despite extensive treatment with
surgery, radiation therapy and chemotherapy. Tumor recurrence is inevitable
after which life prolonging therapies are no longer available. The development
of new treatments for GM is being hampered by inter-and intratumoral
heterogeneity of tumors and their microenvironment, which currently cannot be
predicted accurately with current diagnostics.
Study objective
to establish primary patient derived organoid cultures from GM to study
mechanisms that contribute to aggressive tumor growth and treatment resistance
in primary and recurrent GM.
Study design
Preclinical study, using patient derived glioblastoma tissue
Intervention
not applicable
Study burden and risks
Minimal burden: additional biopsies during a regular neurosurgical procedure
(biopsy or debulking).
no benefit for the patient.
Doctor Tanslaan 12
Maastricht 6229 ET
NL
Doctor Tanslaan 12
Maastricht 6229 ET
NL
Listed location countries
Age
Inclusion criteria
• MRI imaging suggestive for glioblastoma
• > 18 years of age
Exclusion criteria
• Karnofsky index < 70
• Clotting disorders
• Neurosurgical contraindications for gross total resection
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL62648.096.17 |